(Q35184044)

English

Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

0 references

Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Ramin Sadeghi

2

0 references

author name string

Farhad Faridhosseini

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Layla Farid

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Meysam Pourgholami

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

16 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Human Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

216-223

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Elevated inflammation levels in depressed adults with a history of childhood maltreatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Inflammatory markers in depression.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

A meta-analysis of cytokines in major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Cytokines as mediators of depression: what can we learn from animal studies?

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

The role of the innate immune system in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Efficacy of vitamin D supplementation in depression in adults: a systematic review protocol

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Proinflammatory and "resiliency" proteins in the CSF of patients with major depression.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Inflammatory biomarkers and depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Salivary prostaglandin concentrations: possible state indicators for major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Mood disorders and complementary and alternative medicine: a literature review

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Metyrapone in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

CSF Prostaglandin Levels in Depressed and Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

21 January 2018

Depression, immunocompetence, and prostaglandins of the E series

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation, glutamate, and glia in depression: a literature review.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased level of salivary prostaglandins in patients with major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

7 January 2021

based on heuristic

inferred from DOI database lookup

Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating depression to full remission.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2401

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.2401

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35184044&oldid=1645735640"